DK2383285T3 - Peptidsekvenser og sammensætninger - Google Patents
Peptidsekvenser og sammensætninger Download PDFInfo
- Publication number
- DK2383285T3 DK2383285T3 DK11157383.8T DK11157383T DK2383285T3 DK 2383285 T3 DK2383285 T3 DK 2383285T3 DK 11157383 T DK11157383 T DK 11157383T DK 2383285 T3 DK2383285 T3 DK 2383285T3
- Authority
- DK
- Denmark
- Prior art keywords
- drb1
- influenza
- hla
- polypeptide
- dpb1
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Vaccinesammensætning mod influenza, der omfatter et polypeptid og eventuelt en passende excipiens og/eller adjuvans: hvor polypeptidet er SEQ ID 1 eller en sekvens med mindst 85 % homologi med den 32. aminosyresekvens ifølge SEQ ID 1: SEQ ID 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP, og hvor polypeptidet er immunogent hos et hvirveldyr, der udtrykker en større histokompatibilitetskompleks- (MHC) allel og er immunogent over for en flerhed af influenzavirusstammer.
2. Medikamentsammensætning mod influenza, der omfatter et polypeptid og eventuelt en passende excipiens og/eller adjuvans: hvor polypeptidet er SEQ ID 1 eller en sekvens med mindst 85 % homologi med den 32. aminosyresekvens ifølge SEQ ID 1: SEQ ID 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP, og hvor polypeptidet er immunogent hos et hvirveldyr, der udtrykker en større histokompatibilitetskompleks- (MHC) allel og er immunogent over for en flerhed af influenzavirusstammer.
3. Medikament- eller vaccinesammensætning ifølge krav 1 eller krav 2, hvilket polypeptid omfatter en cytotoksisk T-lymfocyt- (CTL) epitop.
4. Medikament- eller vaccinesammensætning ifølge et hvilket som helst af de foregående krav, hvor homologien er 95 % eller mere.
5. Medikament- eller vaccinesammensætning ifølge et hvilket som helst af de foregående krav, der omfatter et yderligere polypeptid.
6. Medikament- eller vaccinesammensætning, som defineret i et hvilket som helst af de foregående krav, til anvendelse i medicin.
7. Medikament- eller vaccinesammensætning som defineret i et hvilket som helst af kravene 1-5 til anvendelse i behandling eller forebyggelse af influenza.
8. Fremgangsmåde til fremstilling af en medikament- eller vaccinesammensætning som defineret i et hvilket som helst af de foregående krav, hvilken fremgangsmåde omfatter blanding af et polypeptid, eller en polypeptidsammensætning, som defineret i et hvilket som helst af kravene 1-5, med en passende excipiens og/eller adjuvans.
9. Polypeptid til anvendelse i behandlingen af influenza, hvor polypeptidet er SEQ ID 1 eller en sekvens med mindst 85 % homologi med den 32. aminosyresekvens ifølge SEQ ID 1: SEQ ID 1 DLEALMEWLKTRPILSPLTKGILGFVFTLTVP, hvor polypeptidet er immunogent hos et hvirveldyr, der udtrykker en større histokompatibilitetskompleks- (MHC) allel, og hvor polypeptidet er immunogent over for en flerhed af influenzavirusstammer, og hvor polypeptidet ikke er et komplet influenzavirusprotein.
10. Polypeptid, fremgangsmåde, medikament, vaccine eller anvendelse ifølge et hvilket som helst af de foregående krav, hvor influenzaen er en influenza A-stamme eller influenzaen er en influenza B-stamme.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0602416A GB0602416D0 (en) | 2006-02-07 | 2006-02-07 | Peptide sequences and compositions |
GBGB0613977.8A GB0613977D0 (en) | 2006-02-07 | 2006-07-13 | Peptide sequences and compositions |
EP07712678A EP1991563B1 (en) | 2006-02-07 | 2007-02-05 | Peptide sequences and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2383285T3 true DK2383285T3 (da) | 2017-08-28 |
Family
ID=38109631
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11157382.0T DK2383284T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK11157383.8T DK2383285T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK17180723.3T DK3263589T5 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK07712678.7T DK1991563T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11157382.0T DK2383284T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17180723.3T DK3263589T5 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
DK07712678.7T DK1991563T3 (da) | 2006-02-07 | 2007-02-05 | Peptidsekvenser og sammensætninger |
Country Status (23)
Country | Link |
---|---|
US (10) | US8475802B2 (da) |
EP (6) | EP2383285B1 (da) |
JP (1) | JP5603551B2 (da) |
KR (1) | KR20080100441A (da) |
CN (3) | CN101395176B (da) |
AP (1) | AP2646A (da) |
AT (1) | ATE534660T1 (da) |
AU (1) | AU2007213562A1 (da) |
BR (1) | BRPI0707543B8 (da) |
CA (1) | CA2641602A1 (da) |
DK (4) | DK2383284T3 (da) |
EA (1) | EA017387B1 (da) |
ES (4) | ES2635590T3 (da) |
GB (1) | GB0613977D0 (da) |
HK (1) | HK1249115A1 (da) |
IL (2) | IL193232A (da) |
MX (1) | MX2008010113A (da) |
NO (1) | NO20083416L (da) |
NZ (1) | NZ570553A (da) |
PL (4) | PL2383285T3 (da) |
PT (1) | PT1991563E (da) |
SG (1) | SG169392A1 (da) |
WO (1) | WO2007091030A2 (da) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
GB0613977D0 (en) | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
BRPI0815008B8 (pt) | 2007-08-02 | 2021-05-25 | Biondvax Pharmaceuticals Ltd | vacinas multiméricas com múltiplos epítopos contra influenza |
US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
AU2008293504B2 (en) | 2007-08-27 | 2012-04-12 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
DK2535428T3 (da) | 2007-10-01 | 2015-11-23 | Longhorn Vaccines & Diagnostics Llc | Biologisk prøvesamlings- og transportsystem, og fremgangsmåder til anvendelse |
GB0719526D0 (en) | 2007-10-05 | 2007-11-14 | Isis Innovation | Compositions and methods |
EP2072529A1 (en) * | 2007-12-21 | 2009-06-24 | basisnote AG | MHC rapid assay used for the customization of odours |
FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
AU2011360572B2 (en) | 2011-02-22 | 2017-03-02 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
WO2013093514A2 (en) * | 2011-12-23 | 2013-06-27 | Retroscreen Virology Ltd | Vaccines - peptides |
CN104203272A (zh) | 2012-01-26 | 2014-12-10 | 长角牛疫苗和诊断有限责任公司 | 复合抗原序列及疫苗 |
TWI623322B (zh) * | 2014-12-10 | 2018-05-11 | 華西亞生醫有限公司 | 用於免疫作用中有效抗體生產的新穎蛋白質結構 |
CA2985652C (en) | 2015-05-14 | 2020-03-10 | Gerald W. FISHER | Rapid methods for the extraction of nucleic acids from biological samples |
CN106310214A (zh) * | 2015-06-30 | 2017-01-11 | 中国科学院上海巴斯德研究所 | 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用 |
JP2019064924A (ja) * | 2016-02-24 | 2019-04-25 | Agc株式会社 | インフルエンザワクチン |
KR101888751B1 (ko) * | 2016-09-22 | 2018-09-21 | 이화여자대학교 산학협력단 | 인플루엔자 b 백신 |
JP2020515283A (ja) * | 2016-12-28 | 2020-05-28 | インブバックス,インコーポレーテッド | インフルエンザワクチン |
EP3730620A4 (en) | 2017-12-21 | 2022-01-05 | Green Biomed, Inc. | CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION |
KR20230041775A (ko) * | 2020-07-21 | 2023-03-24 | 플루젠, 인코퍼레이티드 | 인플루엔자 바이러스 백본 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4981782A (en) | 1987-05-14 | 1991-01-01 | Sri International | Synthetic peptides for diagnosis and prevention of influenza virus infection and their use |
US5741493A (en) * | 1991-01-24 | 1998-04-21 | Pasteur Merieux Serums Et Vaccins | Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive |
IL101639A0 (en) * | 1992-04-17 | 1992-12-30 | Yeda Res & Dev | Recombinant influenza vaccines |
ATE342730T1 (de) * | 1992-08-07 | 2006-11-15 | Pharmexa Inc | Hla bindepeptide und ihre verwendungen |
US20040087521A1 (en) * | 1993-03-18 | 2004-05-06 | Merck & Co., Inc. | Nucleic acid pharmaceuticals-influenza matrix |
IL109664A0 (en) | 1993-05-18 | 1994-08-26 | Rijksuniversiteit | Peptides of human influenza virus for use in human t cell response inducing compositions |
US6939546B2 (en) | 1993-05-21 | 2005-09-06 | The United States Of America As Represented By The Secretary Of The Army | Model for testing immunogenicity of peptides |
FR2718452B1 (fr) * | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
AU3727895A (en) | 1994-09-30 | 1996-04-26 | St. Jude Children's Research Hospital | Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus |
US7269219B1 (en) * | 1997-02-14 | 2007-09-11 | At&T Corp. | Non-linear quantizer for video coding |
IL127331A0 (en) * | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
JP2001151698A (ja) * | 1999-09-10 | 2001-06-05 | Nichiko Pharmaceutical Co Ltd | インフルエンザワクチン |
AU2002223398A1 (en) | 2000-08-10 | 2002-04-08 | Tsinghua University | A vaccine for influenza virus and its preparation |
KR20030061810A (ko) * | 2000-09-25 | 2003-07-22 | 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 | 생균 백신과 제조 방법 |
US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
US20050013826A1 (en) * | 2002-12-20 | 2005-01-20 | Shneider Alexander M. | Vaccine compositions and methods |
JP4617300B2 (ja) * | 2003-02-25 | 2011-01-19 | メディミューン,エルエルシー | インフルエンザワクチン組成物を生成する方法 |
BRPI0407877A (pt) | 2003-03-07 | 2006-03-01 | Merck & Co Inc | conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente |
US8592197B2 (en) * | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
DE102004052026B4 (de) * | 2003-11-07 | 2015-08-27 | Totankako Co., Ltd. | Kollektor |
FR2863758B1 (fr) * | 2003-12-11 | 2006-07-14 | Centre Nat Rech Scient | Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur |
GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
AU2005248361B2 (en) * | 2004-05-18 | 2010-03-11 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
WO2006116082A1 (en) * | 2005-04-21 | 2006-11-02 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
US20070116717A1 (en) | 2005-08-01 | 2007-05-24 | Shneider Alexander M | Influenza vaccine compositions and methods |
EP1988919A4 (en) | 2006-02-02 | 2009-06-10 | Globeimmune Inc | VAKZINE ON YEAST BASE FOR TRIGGERING AN IMMUNE RESPONSE |
GB0613977D0 (en) * | 2006-02-07 | 2006-08-23 | Peptcell Ltd | Peptide sequences and compositions |
-
2006
- 2006-07-13 GB GBGB0613977.8A patent/GB0613977D0/en not_active Ceased
-
2007
- 2007-02-05 CN CN2007800079350A patent/CN101395176B/zh active Active
- 2007-02-05 CN CN201210252429.0A patent/CN102807608B/zh active Active
- 2007-02-05 DK DK11157382.0T patent/DK2383284T3/da active
- 2007-02-05 EP EP11157383.8A patent/EP2383285B1/en active Active
- 2007-02-05 EP EP17210264.2A patent/EP3320918A3/en active Pending
- 2007-02-05 EP EP19192958.7A patent/EP3620463A1/en active Pending
- 2007-02-05 DK DK11157383.8T patent/DK2383285T3/da active
- 2007-02-05 AU AU2007213562A patent/AU2007213562A1/en not_active Abandoned
- 2007-02-05 BR BRPI0707543A patent/BRPI0707543B8/pt active IP Right Grant
- 2007-02-05 PL PL11157383T patent/PL2383285T3/pl unknown
- 2007-02-05 DK DK17180723.3T patent/DK3263589T5/da active
- 2007-02-05 KR KR1020087021658A patent/KR20080100441A/ko not_active Application Discontinuation
- 2007-02-05 ES ES11157383.8T patent/ES2635590T3/es active Active
- 2007-02-05 EP EP11157382.0A patent/EP2383284B1/en active Active
- 2007-02-05 CN CN201110311189.2A patent/CN102382179B/zh active Active
- 2007-02-05 PL PL11157382T patent/PL2383284T3/pl unknown
- 2007-02-05 US US12/278,728 patent/US8475802B2/en active Active
- 2007-02-05 PT PT07712678T patent/PT1991563E/pt unknown
- 2007-02-05 ES ES07712678T patent/ES2374841T3/es active Active
- 2007-02-05 AT AT07712678T patent/ATE534660T1/de active
- 2007-02-05 EA EA200870237A patent/EA017387B1/ru not_active IP Right Cessation
- 2007-02-05 SG SG201100861-2A patent/SG169392A1/en unknown
- 2007-02-05 EP EP07712678A patent/EP1991563B1/en not_active Revoked
- 2007-02-05 EP EP17180723.3A patent/EP3263589B1/en active Active
- 2007-02-05 PL PL07712678T patent/PL1991563T3/pl unknown
- 2007-02-05 MX MX2008010113A patent/MX2008010113A/es active IP Right Grant
- 2007-02-05 JP JP2008553817A patent/JP5603551B2/ja active Active
- 2007-02-05 WO PCT/GB2007/000383 patent/WO2007091030A2/en active Application Filing
- 2007-02-05 AP AP2008004571A patent/AP2646A/xx active
- 2007-02-05 NZ NZ570553A patent/NZ570553A/xx unknown
- 2007-02-05 ES ES11157382.0T patent/ES2611034T3/es active Active
- 2007-02-05 DK DK07712678.7T patent/DK1991563T3/da active
- 2007-02-05 PL PL17180723T patent/PL3263589T3/pl unknown
- 2007-02-05 ES ES17180723T patent/ES2790730T3/es active Active
- 2007-02-05 CA CA002641602A patent/CA2641602A1/en not_active Abandoned
-
2008
- 2008-08-04 IL IL193232A patent/IL193232A/en active IP Right Grant
- 2008-08-04 NO NO20083416A patent/NO20083416L/no not_active Application Discontinuation
-
2012
- 2012-05-07 US US13/465,940 patent/US8444995B2/en active Active
-
2013
- 2013-05-30 US US13/906,232 patent/US9446116B2/en active Active
-
2016
- 2016-08-08 US US15/231,347 patent/US9889191B2/en active Active
-
2017
- 2017-04-23 IL IL251867A patent/IL251867B/en active IP Right Grant
-
2018
- 2018-01-08 US US15/865,214 patent/US10279032B2/en active Active
- 2018-01-22 US US15/876,781 patent/US10335480B2/en active Active
- 2018-07-03 HK HK18108547.1A patent/HK1249115A1/zh unknown
-
2019
- 2019-03-07 US US16/295,488 patent/US10765734B2/en active Active
- 2019-08-14 US US16/540,811 patent/US20190365883A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/013,000 patent/US11439702B2/en active Active
-
2022
- 2022-09-09 US US17/931,017 patent/US20230233660A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2383285T3 (da) | Peptidsekvenser og sammensætninger | |
DK2004676T3 (da) | Peptider af regulatoriske eller accessoriske proteiner af hiv, sammensætninger og anvendelse deraf | |
AU2013201008C1 (en) | Peptide sequences and compositions |